Skip to main content

Table 1 Baseline information of male patients with HIV (n = 61)

From: Gradual increasing dyslipidemia in treatment-naive male patients with human immunodeficiency virus and treated with tenofovir plus lamivudine plus efavirenz for 3 years

Variable

χ ± SD or cases (%)

Range

Age (years)

32.05 ± 8.38

20–58

Gender (male, %)

61 (100%)

 

Infection duration (months)

11.16 ± 1.19

1–86

T lymphocyte subsets

  

 CD3+ count (cells/µL)

1433.98 ± 595.35

470–3074

 CD3+CD4+ count (cells/µL)

313.87 ± 118.473

54–499

 CD3+CD4+ percentage (%)

19.78 ± 6.83

1.40–43.40

 CD3+CD8+ count (cells/µL)

1119.70 ± 605.0

360–2456

 CD3+CD8+ percentage (%)

69.97 ± 13.80

36.13–97.20

 Virus load of HIVRNAa

41772.77 ± 10.38

895.00–505987.00

Metabolic parameters

  

 TG (mmol/L)

1.68 ± 1.23

0.39–16.81

 TC (mmol/L)

4.20 ± 0.72

2.38–6.09

 LDL-c (mmol/L)

2.61 ± 0.68

0.92–4.71

 HDL-c (mmol/L)

1.12 ± 0.24

0.57–1.77

 UA (µmol/L)

310.72 ± 68.65

143–506

Anthropometric parameters

  

 Body weight (kg)

62.41 ± 10.53

46–85

 Body mass index (kg/m2)

21.38 ± 2.82

16.80–28.20

 Body fat percentage (%)

15.99 ± 6.32

3–28.4

 Body fat weight (kg)

10.40 ± 5.33

1.4–22.10

 Body nonfat weight (kg)

51.82 ± 6.67

35.8–64.7

 Baseline body mass status

  

 Body mass index<18 kg/m2

3 (4.92)

 

 24 kg/m2 ≥ Body mass index ≥ 18 kg/m2

49 (80.33)

 

 Body mass index > 24 kg/m2

9 (14.75)

 
  1. TG, triglyceride; TC, total cholesterol; LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol; UA, uric acid
  2. aLogarithmic transformation before statistical analysis for nonnormally distributed data